cr8020
mAbexperimental
Clinical trial activity
4 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2013 (NCT01756950)
Timeline
Indications
Mechanism of action
- Influenza virusANTAGONIST
Influenza virus antagonist
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- cr8020
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01992276 | Phase 2 | Dec 1, 2013 | Crucell, National Institutes of Health (NIH) |
| NCT02015533 | Phase 1 | Dec 1, 2013 | Janssen Pharmaceutica NV, Johnson and Johnson |
| NCT01938352 | Phase 2 | Sep 1, 2013 | Crucell, hVIVO Services Limited |
| NCT01756950 | Phase 1 | Jan 1, 2013 | Crucell, IQVIA, National Institute of Allergy and Infectious Diseases (NIAID) |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Crucell | For profit | 3 | 3 | 2 | 2013 |
| hVIVO Services Limited | For profit | 1 | 0 | 1 | 2013 |
| IQVIA | For profit | 1 | 0 | 1 | 2013 |
| Janssen Pharmaceutica NV | For profit | 1 | 0 | 1 | 2013 |
| Johnson and Johnson | For profit | 1 | 1 | 1 | 2013 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 0 | 1 | 2013 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2013 |
7 organizations
Page 1 / 1